SFL

10/14 (二) 蕭醫師來訪建議.

由 sufang 在 日, 10/26/2014 – 09:14 發表 Pre-published IDO1 要找IHC能用的抗體,可以上 The human protein atlas網站.像以HNSC IDO1而言,就有三個選擇 HPA023072, HPA023149, HPA027772. 素芳提議染100例oral cancer檢體、或是補染40對T/N samples。 2014/10/28: TDO2也有抗體 Antibody HPA039611.   HNSC TDO2.    IDO2 則似乎沒有收錄.

10/14 (二) 蕭醫師來訪建議. Read More »

Dr. George Prendergast’s visit

由 sufang 在 日, 10/26/2014 – 09:25 發表 Pre-published IDO1 TDO2 Time: 10:00~11:30 October 24, 2014 (Fri) Topic: IDO pathways in pathogenic inflammation and immune escape in cancer Speaker: George C. Prendergast, PhD (CV download) Professor, President & CEO, Lankenau Institute for Medical Research Editor-in-Chief, Cancer Research  (他說兩大要件: (1) Pathological relevalence (2) Translational relevance. 若是一堆western

Dr. George Prendergast’s visit Read More »

2014/10/20 CMU Mini-symposium on Transcription, Epigenetics and Stem Cell

Dear All, On behalf of the organization committee, I like to invite you to join 2014 CMU Mini-symposium on Transcription, Epigenetics and Stem Cell to be held at China Medical University at Taichung from 12:30 to 5:30 pm on Oct 20 of 2014. We are very pleased to have three world leading scientists Yi Zhang, Hongkui Deng

2014/10/20 CMU Mini-symposium on Transcription, Epigenetics and Stem Cell Read More »

Oral Cancer 40 T/N 相關

40T/N 相關由 sufang 在 一, 10/06/2014 – 10:21 發表 Older Posts 40TN Ideograms LOH Loss, maybe 1p36.3: MTHFR (ACshort 0.53x folate pathway related) * 1q12-q23: DPT (40TN 0.36x, 4NQO mouse 0.5x, DOK project array上沒有此基因) 3p21.31-21.2: BAP1 (ACshort 0.92x) 3p21.3: RASSF1(ACshort 1.48x) 3q26.3-q27: LAMP3 (ACshort 0.05x) * 4q23: ADH1A, ADH1B, ADH1C (DOK project array上沒有此些基因 40TN 0.33x, 0.08x, 0.14x) 4q28: MAML3 4q31.1: FBXW7 (40TN 0.9x) 9p21.3: CDKN2A (40TN 5.33x) 9q21.13: ALDH1A1 (ACshort 0.8x) 9q34.1: ASS1, FPGS 9q34.3: NOTCH1 (ACshort 0.84x, 40TN 0.93x, qRT-PCR primer

Oral Cancer 40 T/N 相關 Read More »

2015 MOST PPG

2015 MOST PPG 由 sufang 在 五, 10/03/2014 – 13:18 發表  Pre-published   2015 MOST PPG   Tissue microenvironment   TME   整合型行計畫   整合型計畫 2015/05/29 口腔癌整合型計劃主題方向   Janelle Kuo <cckuo@nhri.org.tw>AttachmentsMay 27 (2 days ago)Replyto Shih, 李岳倫, 陳雅雯, David, 林素芳 Chinese (Traditional)English   Translate messageTurn off for: Chinese (Traditional)Dear all這是今天討論的暫訂方向先以這主題思索也先寫上一個暫時性的題目之後大家再努力想出更性感的題目吧哈哈珍   Su-Fang Lin <sflin1@gmail.com>9:25 AM (4 hours ago)Replyto Janelle, Shih,

2015 MOST PPG Read More »

IDO1 expression in OSCC

由 natsumi 在 四, 09/18/2014 – 14:58 發表 Pre-published IDO1 #1由 sufang 在 五, 10/24/2014 – 14:50 發表。Dr. George Prendergast’s visit Time: 10:00~11:30 October 24, 2014 (Fri) Topic: IDO pathways in pathogenic inflammation and immune escape in cancer Speaker: George C. Prendergast, PhD (CV download)               Professor, President & CEO,                Lankenau Institute for Medical Research

IDO1 expression in OSCC Read More »

為何你會收到來自Our Mission的email notification

簡單說明一下這個Blog有個很體貼的設定,就是說當任何一則新文發表後,它自動會通知10個email address; 另外,新的comment也是,任何一則comment發表後,網站會自動通知10個email address。 目前我們這個網站有23個作者。我把學生和比較新的人的email address放在前10名,就是一旦有新文po上去,他們立刻可以收到通知。然後,請po文的人記得在自己文章回一個comment, 註明 “Hi” 或任何text, 這樣子後面10個email的人就可循線來追新文! Well, 現在還有三個人的email放不上去,所以若有人能利用RSS追蹤此Bolg的新聞動態,那就不需要這個notification系統,抑或有覺得不需要這樣子通知你來讀blog的人,這類善心人士請務必通知SFL, 讓我空出位置來放仍在waiting list的email address. 感謝。——————– 3 Comments Close this windowJump to comment form 1 – 3 of 3 SFL said… Hi, 請抽個空看看我的主文!! September 4, 2014 at 9:34 AM DATO Chang said… 是往後提醒十個人!? September 4, 2014 at 11:20 PM ingrid said… 我想是SFLpo文可以通知1-10號SFL在SFL自己po文回應可以通知11-20號DATO在SFLpo文回應可以通知11-20號 (因為我被通知到了)但仍有21-23號都不會被通知到這則新po文 September 5,

為何你會收到來自Our Mission的email notification Read More »

NICR LIN LAB

由 sufang 在 四, 08/21/2014 – 09:57 發表 Pre-published Temp Head and neck cancers, including oral cancer and nasopharyngeal carcinoma (NPC), are caused by known extrinsic factors and develop within pre-neoplastic fields of genetically or epigenetically altered cells. In Taiwan, betel quid chewing in oral cancer and Epstein-Barr virus (EBV) infection in NPC are thought

NICR LIN LAB Read More »

Scroll to Top